Author:
Kerl Katrin,Kerl Helmut,Heinzerling Lucie
Publisher
Springer International Publishing
Reference26 articles.
1. Barrios DM, Do MH, Phillips GS, Postow MA, Akaike T, Nghiem P, Lacouture ME. Immune checkpoint inhibitors to treat cutaneous malignancies. J Am Acad Dermatol. 2020;83(5):1239–53.
2. Heinzerling L, de Toni EN, Schett G, Hundorfean G, Zimmer L. Checkpoint inhibitors: the diagnosis and treatment of side effects. Deutsches Ärzteblatt International | Dtsch Arztebl Int. 2019;116:119–26.
3. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345–56.
4. Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390:1853–62.
5. Long GV, Atkinson V, Cebon JS, et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017;18:1202–10.